(RHK) RHÖN-KLINIKUM - Ratings and Ratios
Healthcare Services, Hospital Care, Medical Centers, Rehabilitation Services
RHK EPS (Earnings per Share)
RHK Revenue
Description: RHK RHÖN-KLINIKUM
RHÖN-KLINIKUM Aktiengesellschaft is a German healthcare company providing a range of medical services through its hospitals, medical care centers, and rehabilitation facilities. With a history dating back to 1973, the company is headquartered in Bad Neustadt an der Saale, Germany.
From a financial perspective, RHÖN-KLINIKUM has a market capitalization of approximately €803.26 million, indicating a mid-cap stock. The companys price-to-earnings ratio stands at 20.00, suggesting a relatively stable valuation. However, the forward P/E ratio of 42.02 may indicate expected growth in earnings. The return on equity (RoE) is 3.08%, which is relatively low and may indicate that the company is not generating sufficient profits from its equity.
To further analyze RHÖN-KLINIKUMs performance, we can examine key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio. A review of the companys financial statements reveals that revenue growth has been moderate in recent years. The EBITDA margin, a measure of profitability, is around 10-12%, which is relatively stable for a healthcare company. The debt-to-equity ratio is approximately 0.5, indicating a moderate level of indebtedness.
From an operational perspective, RHÖN-KLINIKUMs hospital network and medical care centers provide a diversified revenue stream. The companys focus on providing high-quality patient care and its presence in the German healthcare market, which is known for its high standards and strong demand, are positive factors. However, the companys ability to navigate the complex regulatory environment and adapt to changing healthcare policies will be crucial to its future success.
To make an informed investment decision, it is essential to monitor RHÖN-KLINIKUMs financial performance, operational efficiency, and industry trends. A thorough analysis of the companys strengths, weaknesses, opportunities, and threats (SWOT analysis) would provide a more comprehensive understanding of its investment potential.
Additional Sources for RHK Stock
RHK Stock Overview
| Market Cap in USD | 948m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
RHK Stock Ratings
| Growth Rating | -32.3 |
| Fundamental | 37.3 |
| Dividend Rating | 6.46 |
| Rel. Strength | 5.65 |
| Analysts | - |
| Fair Price Momentum | 10.84 EUR |
| Fair Price DCF | 17.90 EUR |
RHK Dividends
| Dividend Yield 12m | 0.70% |
| Yield on Cost 5y | 0.51% |
| Annual Growth 5y | % |
| Payout Consistency | 71.6% |
| Payout Ratio | 16.9% |
RHK Growth Ratios
| Growth Correlation 3m | -80.5% |
| Growth Correlation 12m | 55.6% |
| Growth Correlation 5y | -80% |
| CAGR 5y | -7.07% |
| CAGR/Max DD 5y | -0.15 |
| Sharpe Ratio 12m | -0.11 |
| Alpha | -3.40 |
| Beta | 0.080 |
| Volatility | 33.64% |
| Current Volume | 0.3k |
| Average Volume 20d | 0.4k |
As of July 04, 2025, the stock is trading at EUR 12.20 with a total of 303 shares traded.
Over the past week, the price has changed by +4.27%, over one month by +0.00%, over three months by -10.87% and over the past year by +0.82%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, RHÖN-KLINIKUM (XETRA:RHK) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.34 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RHK is around 10.84 EUR . This means that RHK is currently overvalued and has a potential downside of -11.15%.
RHÖN-KLINIKUM has no consensus analysts rating.
According to our own proprietary Forecast Model, RHK RHÖN-KLINIKUM will be worth about 11.7 in July 2026. The stock is currently trading at 12.20. This means that the stock has a potential downside of -4.02%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16 | 31.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 11.7 | -4% |